Can you please explain to me how this will happen, as Axogen will be required to pay ever increasing amounts of money to PDL. The current revenue trajectory does not seem to indicate an offset as compared to the PDL obligation. At some point to be successful, revenue must be greater than expenses.
How is it that the "executives" continue to pay themselves such exorbitant pay packages with
such poor results?
Never mind the 22 sales reps - what about executive compensation?????
I remain confused - If we look at compensation for top management vs profitability there seems to
be a disconnect. Why is management compensation in real $$ so high? Why aren't they rewarded in
stock options freeing up the cash to build the business?
What constitutes "good numbers"? Please help me understand sales vs debt vs time on the market vs buy out
If there was a buy out - what $ to cover existing debt
I am still confused about the amount of debt, length of time product has been on the market, sales per representative. Any answers?
What was the size of the graft used to save the leg? Is this a common procedure? What was the cost of the grafts used? What is the projected yearly sales volume in this type of procedure?
If it is such a good opportunity, why didn't STRYKER buy it?
Why hasn't BAXTER bought it ?
Why hasn't INTERGRA bought it?
Why hasn't LIFECELL bought it?
BECAUSE THE PERIPHERAL NERVE REPAIR MARKET IS TOO SMALL!
"On August 14, 2012, the Company entered into a two year Interim Revenue Interest Purchase Agreement (the "Interim Royalty Contract") with PDL BioPharma, Inc. ("PDL"), pursuant to which PDL paid the Company $1,750,000 in exchange for the purchase of specified "Acquired Revenues," from the Company in an amount equal to the following: (i) during the period from August 1, 2012 to December 31, 2012, 3% of the Company's Net Revenue, per month, and (ii) during the period from January 1, 2013 to August 31, 2014, the greater of 5% of the Company's Net Revenue, or $112,257 per month. The Company shall repurchase the Acquired Revenues and terminate the Interim Royalty Contract at any time, in the event the Company (i) receives equity or debt financing in an aggregate amount greater than $5,000,000 from an investor(s) other than PDL, or (ii) experiences a change in control (as defined in the Interim Royalty Contract). Upon repurchase of the Acquired Revenues in such circumstances, the Company is required to pay PDL the outstanding balance under the Interim Royalty Contract as of the payment date, any accrued but unpaid Acquired Revenues through the payment date, and a $150,000 fee."
How can this be a good point?
Have you read the latest financials?
How many days before the money is gone?